NeuroKaire Gets CLIA Certification for Precision Medicine in Psychiatry and Neurology
The CLIA-certified lab launched a pharmacogenetic assay to empower tailored treatments for psychiatric, neurological, and related conditions.
Read MorePosted by Andy Lundin | Nov 25, 2024 | Company News |
The CLIA-certified lab launched a pharmacogenetic assay to empower tailored treatments for psychiatric, neurological, and related conditions.
Read MorePosted by Andy Lundin | Nov 22, 2024 | Molecular Diagnostics |
A new study shows how genetic testing could personalize postoperative pain management by identifying genetic predispositions to opioid use.
Read MorePosted by Andy Lundin | Nov 21, 2024 | Molecular Diagnostics |
Delve Bio found that mNGS identified more pathogens from cerebrospinal fluid samples than all conventional diagnostic methods combined.
Read MorePosted by Andy Lundin | Nov 21, 2024 | Lung Cancer, Molecular Diagnostics |
Biofidelity’s test delivers comprehensive genomic profiling for NSCLC patients from tissue or liquid biopsy samples within two days.
Read MorePosted by Andy Lundin | Nov 19, 2024 | Dementias & Alzheimer’s |
A new capillary blood test offers a simple, mail-in method to detect Alzheimer’s biomarkers, paving the way for accessible global testing.
Read More